Long acting polycaprolactone based parenteral formulation of aripiprazole targeting behavioral and biochemical deficit in schizophrenia.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2020.12.028
Abstract: Schizophrenia is a neurodevelopmental disorder which is expressed in the form of disturbed behaviour and abnormal mental functions. Patient's non-adherence to the medicine is the main cause of failure of drug therapy and increases incidence… read more here.
Keywords: schizophrenia; long acting; polycaprolactone based; acting polycaprolactone ... See more keywords